The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study
Main finding · Any fracture, adjustedResult — go to the resultOdds ratio 0.94 CI 0.90–0.97Authors' conclusion
GLP-1 receptor agonists may reduce fracture risk, suggesting a potential protective effect on bone health.
Study context
- Population
- Persons aged 30–90 years in Denmark with a fracture between 2017 and 2021 and matched fracture-free controls
- Participants
- 337,648 vs 675,296
- Comparison
- GLP-1 receptor agonist use in fracture cases vs fracture-free controls
- Fracture casesn = 337,648
- Controlsn = 675,296reference
- Outcome
- Any fracture and major osteoporotic fracture (MOF) associated with GLP-1 receptor agonist use
Methodological detailsnationwide, matched 1:2 by sex and year of birth, conditional logistic regression
- Nationwide
- Matched 1:2 by sex and year of birth
- Conditional logistic regression
Main finding
Any fracture, adjusted
Odds ratio
0.94
CI 0.90–0.97
Fracture casesvs Controls
OR 0.94 (CI 0.90–0.97)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| MOF, adjustedAdjusted for relevant risk factors | 0.88 (0.83–0.94) | |
| Any fracture, unadjusted | 1.00 (0.97–1.04) | |
| MOF, unadjusted | 0.96 (0.90–1.02) | |
| 0.512Odds ratio (log scale) |
Original publication
The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study. Osteoporos Int. Published 18 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →